直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Claim Construction

2016

ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition

By Mark J. Feldstein, Ph.D.; Krista E. Bianco

Claim construction is the process in which courts interpret the meaning and scope of a patent's claims. Since the claims "define the invention to which the patentee is entitled the right to exclude," construing the claims can be a critical step in determining the outcome of almost all patent litigations. In fact, the first step of any infringement or validity analysis is to determine the meaning of the claims (i.e., what the claims encompass and what they do not). Only after the boundaries of the claims have been determined can a judge or jury decide whether the allegedly infringing product or process falls within the scope of the patentee's claims, whether the claims are adequately described in the specification, or whether the claims are invalid in view of the prior art. From a practical standpoint, once the scope of the patentee's rights has been determined, the question of infringement can often be resolved without trial, often by agreement of the parties or on summary judgment.

This chapter begins by setting forth the general principles of the claim construction analysis. Once the basic rules for interpreting the meaning of the claims have been explained, this chapter addresses the timing and procedural aspects of the claim construction analysis. Mark J. Feldstein, Ph.D. discusses various strategic considerations the parties to an Abbreviated New Drug Application (ANDA) case should address once the claims have been construed.

 

Tags

claim construction, infringement

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Professionals

Mark J. Feldstein, Ph.D.
Partner
Washington, DC
+1 202 408 4092
Email

Originally printed in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition in 2016. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.

Related Insights

Seminar

U.S. Patent Litigation 2026: Key Developments, Strategic Trends, and Winning Before Trial

November 6, 2026

Taipei

Federal Circuit IP Blog

Federal Circuit Affirms Invalidity Challenge to Scientifically Impossible Claim Language on Enablement Grounds

October 23, 2026

Federal Circuit IP Blog

Federal Circuit Dismisses Non-Infringement Appeal of Only Certain Patent Claims, Denies Judge Reassignment

October 23, 2026

Federal Circuit IP Blog

Warning Signs Ignored: Federal Circuit Vacates Denial of Rule 11 Sanctions and Attorneys’ Fees

October 23, 2026

Federal Circuit IP Blog

Private Sale Gets No Safe Harbor from §102(b)(1)(B)

October 14, 2026

Articles

EPR Academy, Part 5 of 6: Special Considerations for Third-Party Requesters

October 14, 2026

Articles

Who Is a “Consumer?” The Supreme Court Takes Up the Video Privacy Protection Act

October 12, 2026

INCONTESTABLE® Blog

Federal Court Orders Rebel Creamery to Redesign Packaging and Disgorge $23.8 Million in Van Leeuwen Trade Dress Case

October 7, 2026

Articles

California Court Considers CIPA’s Application to Online Tracking as New Law Limits Private Actions

October 7, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP